

**In The Claims**

1-44. (canceled)

45. (currently amended) An anabolic medicament for treating a damaged tissue, the medicament comprising:

- a) at least one ~~mucopolysaccharide~~ extracellular matrix compound in an amount effective in the damaged tissue as anti-neo-inflammatory and anti-neo-angiogenetic agent,
- b) at least one polar surface active lipid; and
- c) a plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is characteristic of human breast ~~tissue~~milk protein, and wherein no more than 10% of the amino acids are in D-form.

46. (previously presented) The medicament according to claim 45, wherein said extracellular matrix compound is synthetically produced.

47. (previously presented) The medicament according to claim 45, wherein said extracellular matrix compound is obtained from a cellular or tissue source.

48. (previously presented) The medicament according to claim 45, wherein said polar surface active lipid is obtained from a cellular or tissue source.

49. (previously presented) The medicament according to claim 45, wherein said polar surface active lipid is synthetically produced.

50. (cancelled)

51. (currently amended) The medicament according to claim 45, wherein said plurality of amino acids are obtained from a cellular or tissue source.

52. (previously presented) The medicament according to claim 47, wherein said cellular or tissue source is selected from the group consisting of a cell membrane, a tissue and an organ.

53. (currently amended) The medicament according to claim 45, wherein said extracellular matrix compound is selected from the group consisting of a ~~glucosaminoglycan~~ glycosaminoglycan, a collagen, cartilage, chondroitin sulfate, a glycoprotein, and a ~~proteoglycan~~ proteoglycan.

54. (previously presented) The medicament according to claim 45, wherein said polar surface active lipid is selected from the group consisting of a phosholipid, a glycolipid, and a lipoprotein.

55.-64. (canceled)

65. (previously presented) The medicament according to claim 45, further comprising a sterile vehicle.

66. (previously presented) The medicament according to claim 48, wherein said cellular or tissue source is selected from the group consisting of a cell membrane, a tissue, and an organ.

67. (previously presented) The medicament according to claim 51, wherein said cellular or tissue source is selected from the group consisting of a cell membrane, a tissue, and an organ.

68. (previously presented) The medicament according to claim 49, wherein said polar surface active lipid is selected from a group consisting of a phosholipid, a glycolipid, and a lipoprotein.

69. (previously presented) The medicament according to claim 48, wherein said polar surface active lipid is selected from the group consisting of a phosholipid, a glycolipid, and lipoprotein.

70. (previously presented) The medicament according to claim 48, wherein at least one extracellular matrix compound, at least one polar surface active lipid, and at least one amino acid associate through a molecular bonding force.

71. (currently amended) The medicament according to claim 70, wherein said molecular bonding force is selected from the group consisting of ~~electron affinity~~, van der Waals[[.]] and ~~zwitterionic~~.

72.-73 (canceled)

74. (currently amended) The medicament according to claim 45 further comprising at least one of (a) ~~at least one a~~ mineral; (b) ~~at least one a~~ vitamin; (c) ~~at least one an~~ antioxidant; (d) omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and (j) collagen.

75. (canceled)

76. (currently amended) The medicament according to claim 48, further comprising at least one of (a) ~~at least one a~~ mineral; (b) ~~at least one a~~ vitamin; (c) ~~at least one an~~ antioxidant; (d) omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and (j) collagen.

77-96. (cancelled)

97. (previously presented) The medicament according to claim 45, further comprising gamma amino butyric acid or L-carnitine.

98. (previously presented) The medicament according to claim 45 further comprising a fatty acid selected from the group consisting of linoleic acid and linolenic acid.

99.-103. (canceled)

104. (previously presented) The medicament of claim 45, wherein the damaged tissue is selected from the group consisting of skin, eye, liver, gastro-intestinal, kidney, and lung.

105. (previously presented) The medicament of claim 104, wherein the gastro-intestinal tissue is bowel tissue.

106. (previously presented) The medicament of claim 105, wherein the bowel tissue is damaged from regional ileitis (Crohn's Disease), inflammatory bowel disease, ulcerative colitis, or mucous colitis.